Patents by Inventor Xuechun Zhang
Xuechun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965904Abstract: A sample to be measured is placed in a medium solution between two circular magnets to ensure that the sample to be measured is levitated in a set circular area between the two circular magnets, and a levitation position of the sample to be measured in the magnetic field is measured. The density of the sample is calculated according to formula (I): ? s = ? m + ? m - ? s g ? ? 0 ? ( B r ? ? B z ? r + B z ? ? B z ? z ) . Compared to the prior art, the method of the present disclosure provides a novel method for measuring a density of a substance, in which the involved device is easy to operate and has low cost, and the measurement results are easy to observe and have high accuracy.Type: GrantFiled: January 13, 2021Date of Patent: April 23, 2024Assignee: Zhejiang UniversityInventors: Peng Zhao, Chengqian Zhang, Fu Gu, Xuechun Zhang, Jun Xie, Jianzhong Fu
-
Publication number: 20220326001Abstract: The present disclosure discloses a magnetic flexible tactile sensor structure based on a folding magnetization method, which comprises a flexible body containing a permanent magnetic material; the flexible body has a negative Poisson's ratio structure, and its set area has undergone folding magnetization treatment. The present disclosure also discloses a sensor composed of the above-mentioned sensing structure. The sensor provided by the present disclosure can be applied in sealed and wireless scenarios. The present disclosure can detect the size and position of force. The flexible sensor has broad prospects in the application of the touch skin of robots. The function between the magnetic field-based sensing magnet and the Hall element is contactless. In some cases where it is difficult to establish isolation of the connection lines, it can also be used as an unfettered tactile sensor.Type: ApplicationFiled: March 23, 2022Publication date: October 13, 2022Inventors: Peng ZHAO, Hao HU, Xuechun ZHANG, Chengqian ZHANG, Tingyu WANG, Jianzhong FU
-
Publication number: 20210215589Abstract: A sample to be measured is placed in a medium solution between two circular magnets to ensure that the sample to be measured is levitated in a set circular area between the two circular magnets, and a levitation position of the sample to be measured in the magnetic field is measured. The density of the sample is calculated according to formula (I): ? s = ? m + ? m - ? s g ? ? 0 ? ( B r ? ? B z ? r + B z ? ? B z ? z ) . Compared to the prior art, the method of the present disclosure provides a novel method for measuring a density of a substance, in which the involved device is easy to operate and has low cost, and the measurement results are easy to observe and have high accuracy.Type: ApplicationFiled: January 13, 2021Publication date: July 15, 2021Inventors: Peng ZHAO, Chengqian ZHANG, Fu GU, Xuechun ZHANG, Jun XIE, Jianzhong FU
-
Publication number: 20170275264Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.Type: ApplicationFiled: March 7, 2017Publication date: September 28, 2017Applicant: NOVARTIS AGInventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Haiyang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG
-
Patent number: 9624192Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.Type: GrantFiled: February 22, 2016Date of Patent: April 18, 2017Assignee: Novartis AGInventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tie-Lin Wang, Xiaoyang Wang, Xuechun Zhang
-
Publication number: 20160244426Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.Type: ApplicationFiled: February 22, 2016Publication date: August 25, 2016Applicant: NOVARTIS AGInventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Hayang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG
-
Patent number: 9273026Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.Type: GrantFiled: April 14, 2015Date of Patent: March 1, 2016Assignee: Novartis AGInventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Hayang Jiang, Piotr Karpinski, Thomas J. Troxler, Tie-Lin Wang, Xiaoyang Wang, Xuechun Zhang
-
Patent number: 9216182Abstract: The invention relates to compound of the formula I (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation and to medicaments comprising it for treating diseases connected to the inhibition of H3 receptor.Type: GrantFiled: October 8, 2012Date of Patent: December 22, 2015Assignee: Novartis AGInventors: Tie-Lin Wang, Xuechun Zhang
-
Publication number: 20150218127Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.Type: ApplicationFiled: April 14, 2015Publication date: August 6, 2015Applicant: NOVARTIS AGInventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Hayang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Telin WANG, Xiaoyang WANG, Xuechun ZHANG
-
Patent number: 9034874Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.Type: GrantFiled: July 17, 2013Date of Patent: May 19, 2015Assignee: NOVARTIS AGInventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tielin Wang, Xiaoyang Wang, Xuechun Zhang
-
Publication number: 20140235609Abstract: The invention relates to compound of the formula I (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation and to medicaments comprising it for treating diseases connected to tehinhibition of H3 receptor.Type: ApplicationFiled: October 8, 2012Publication date: August 21, 2014Inventors: Tie-Lin Wang, Xuechun Zhang
-
Publication number: 20140163036Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.Type: ApplicationFiled: July 17, 2013Publication date: June 12, 2014Inventors: Yves AUBERSON, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tielin Wang, Xiaoyang Wang, Xuechun Zhang
-
Publication number: 20100008866Abstract: Cis-cyclohexyl substituted pyrimidinone derivatives are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: May 6, 2009Publication date: January 14, 2010Applicant: Neurogen CorporationInventors: Charles A. Blum, Manuka Ghosh, Isamir Martinez, Xuechun Zhang, Xiaozhang Zheng
-
Publication number: 20080015196Abstract: Novel aryl substituted imidazopyrazines, imidazopyrimidines, and imidazopyridines are provided. Such compounds can act as selective modulators of CRF receptors. The imidazopyrazines, imidazopyrimidines, and imidazopyridines compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.Type: ApplicationFiled: April 15, 2005Publication date: January 17, 2008Applicant: NEUROGEN CORPORATIONInventors: Dario Doller, Lu Zhang, Ping Ge, Yasuchika Yamaguchi, Raymond Horvath, Xuechun Zhang
-
Publication number: 20070043056Abstract: Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.Type: ApplicationFiled: October 23, 2006Publication date: February 22, 2007Applicant: Neurogen CorporationInventors: Taeyoung Yoon, Ping Ge, Stephane De Lombaert, Raymond Horvath, Dario Doller, Kevin Hodgetts, Lu Yan Zhang, Bernd Kaiser, Xuechun Zhang, Cunyu Zhang, Jim Darrow, Yasuchika Yamaguchi
-
Patent number: 7179807Abstract: Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators or CRF receptors. Compounds of the invention are provided by the following formula: The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphercal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.Type: GrantFiled: August 20, 2003Date of Patent: February 20, 2007Assignee: Neurogen CorporationInventors: Taeyoung Yoon, Ping Ge, Stéphane De Lombaert, Raymond F. Horvath, Dario Doller, Kevin J. Hodgetts, Lu Yan Zhang, Bernd Kaiser, Xuechun Zhang, Yasuchika Yamaguchi, Cunyu Zhang, Jim Darrow
-
Publication number: 20060199823Abstract: Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.Type: ApplicationFiled: March 24, 2006Publication date: September 7, 2006Applicant: Neurogen CorporationInventors: Ping Ge, Raymond Horvath, Lu Zhang, Yasuchika Yamaguchi, Bernd Kaiser, Xuechun Zhang, Suoming Zhang, He Zhao
-
Publication number: 20060063938Abstract: The present invention relates to compounds of formula I: useful HIV infection, AIDS, and other similar diseases. These compounds include inhibitors of the retroviral integrase enzyme that are useful in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce incorporation of a donor DNA into a receiving DNA.Type: ApplicationFiled: December 6, 2002Publication date: March 23, 2006Inventors: Terrence Burke, Xuechun Zhang, Godwin Pais, Evguenia Svarovskaia, Vinay Pathak, Christophe Marchand, Yves Pommier
-
Publication number: 20050113379Abstract: Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.Type: ApplicationFiled: September 3, 2004Publication date: May 26, 2005Inventors: Ping Ge, Raymond Horvath, Lu Yan Zhang, Yasuchika Yamaguchi, Bernd Kaiser, Xuechun Zhang, Suoming Zhang, He Zhao, Stanly John, Neil Moorcroft, Greg Shutske